MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, KURA had -$75,363K decrease in cash & cash equivalents over the period. -$70,696K in free cash flow.

Cash Flow Overview

Change in Cash
-$75,363K
Free Cash flow
-$70,696K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of short-term investm...
    • Contract liabilities
    • Share-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Purchases of short-term investme...
    • Prepaid expenses and other curre...
    • Amortization of premium and accr...
    • Others

Cash Flow
2025-12-31
Total revenue
67,482
Total operating expenses
371,113
Interest and other income, net
26,774
Interest expense
1,512
Income tax expense
297
Net loss
-278,666
Share-based compensation expense
37,108
Amortization of premium and accretion of discounts on short-term investments, net
8,488
Depreciation expense
1,032
Non-cash interest expense
515
Accounts receivable, net
6,744
Inventory
413
Prepaid expenses and other current assets
15,950
Accounts payable
4,499
Accrued expenses and other current liabilities
12,654
Operating lease right-of-use and other long-term assets
6,363
Other long-term liabilities
1,043
Contract liabilities
195,715
Net cash (used in) provided by operating activities
-64,058
Purchases of short-term investments
761,588
Maturities of short-term investments
755,128
Purchases of property and equipment
6,638
Net cash (used in) provided by investing activities
-13,098
Proceeds from issuance of stock under equity plans
1,793
Proceeds from issuances of common stock and pre-funded warrants, net of offering costs
0
Net cash provided by financing activities
1,793
Net (decrease) increase in cash and cash equivalents
-75,363
Cash and cash equivalents at beginning of period
224,462
Cash and cash equivalents at end of period
149,099
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofstock under equity...$1,793K Net cash provided byfinancing activities$1,793K Net (decrease)increase in cash and cash...-$75,363K Canceled cashflow$1,793K Contract liabilities$195,715K Share-based compensationexpense$37,108K Accrued expenses andother current...$12,654K Accounts payable$4,499K Other long-termliabilities$1,043K Depreciation expense$1,032K Non-cash interestexpense$515K Maturities of short-terminvestments$755,128K Net cash (used in)provided by operating...-$64,058K Net cash (used in)provided by investing...-$13,098K Canceled cashflow$252,566K Canceled cashflow$755,128K Total revenue$67,482K Interest and otherincome, net$26,774K Net loss-$278,666K Purchases of short-terminvestments$761,588K Canceled cashflow$94,256K Prepaid expenses andother current assets$15,950K Amortization of premium andaccretion of discounts on...$8,488K Accounts receivable, net$6,744K Operating leaseright-of-use and other...$6,363K Inventory$413K Purchases of property andequipment$6,638K Total operatingexpenses$371,113K Interest expense$1,512K Income tax expense$297K

Kura Oncology, Inc. (KURA)

Kura Oncology, Inc. (KURA)